Replies to post #214015 on Biotech Values

[DewDiligence]

RIGL -17% on phase-2 miss:

https://finance.yahoo.com/news/rigel-announces-topline-data-proof-110000828.html

[DewDiligence]

FDA approves RIGL’s Tavalisse (fostamatinib) for second-line ITP; the label:

https://t.co/xd0FmWp7mf

RIGL erroneously posted the approval on its website last week (#msg-140003694).